Sign In

Chris Wagner

Chief Executive Officer at ImmunoFlex

Chris Wagner is the Chief Executive Officer and Board Chair at ImmunoFlex, a company focused on developing methods to improve the success rate of the immune system.1 He has over 25 years of experience in the life sciences industry, with a demonstrated record of creating novel strategies, securing financing, and leading international execution.1

Wagner's career highlights include:

  1. President of 23 Health, a consultancy and family office with active investments in biotech, digital health, genomics, and immunology (February 2009 - Present).1

  2. Founder, President & CEO of Imagia Canexia Health, where he built a bioinformatics company based on genomics and automated drug recommendations (January 2014 - February 2022).1

  3. CEO and Board Member of Emerald Health Therapeutics Inc., where he grew the public company's market capitalization from $0.1B to $0.4B (October 2017 - January 2019).1

  4. President, CEO, and Board Member of Sirius Genomics - Eli Lilly and Company (2007 - 2013).1

  5. Founder and Vice President of Marketing and Business Development at Aspreva Pharmaceuticals, where he helped grow the company's valuation from $3M to over $1B (2001 - 2006).1

Wagner holds a BSc in Organic Chemistry from the University of British Columbia and has completed executive education programs at Northwestern University's Kellogg School of Management and Wharton Business School.1 He is also an Accredited Director (Acc.Dir) certified by the Chartered Governance Institute.1

Related Questions

What are Chris Wagner's key achievements at ImmunoFlex?
How did Chris Wagner's leadership impact the growth of 23 Health?
What strategies has Chris Wagner implemented at ImmunoFlex?
Can you provide more details about Chris Wagner's role at Melio Peptide Systems Inc?
What is Chris Wagner's educational background?
Chris Wagner
Chris Wagner, photo 1
Chris Wagner, photo 2
Add to my network

Location

Vancouver, British Columbia, Canada